Diabetes Care, Vol 9, Issue 2 129-133, Copyright © 1986 by American Diabetes Association

ARTICLES

Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes

LC Groop, R Pelkonen, S Koskimies, GF Bottazzo and D Doniach

To study the etiopathogenesis of secondary drug failure to treatment with oral antidiabetic agents in patients with non-insulin-dependent diabetes (NIDD) we compared 60 "nonresponders" with 60 "responders" to treatment with oral drugs. Secondary drug failure was defined as mean diurnal blood glucose greater than 12 mmol/L after an initial good response of greater than or equal to 2 yr. The nonresponders were characterized by 50% lower C-peptide concentrations than the responders (P less than 0.001). We could not, however, define a critical C-peptide level to discriminate between patients requiring and not requiring insulin therapy. There was a wide overlap of individual C-peptide values between responders and nonresponders that attenuates the clinical value of single C-peptide measurements in predicting therapy. Only by serial measurements over a period of time was it possible to achieve information about changes in beta cell function. The nonresponders showed increased frequency of islet cell (P less than 0.01), thyroid antimicrosomal (P less than 0.01), and gastric parietal cell antibodies (P less than 0.02). In nonresponders, HLA-antigen B8 was increased (P less than 0.05) and HLA-B7 decreased (P less than 0.01) compared with frequencies of responders. In conclusion, impaired beta cell function is a characteristic feature of many, but not all, NIDD patients who fail on treatment with oral antidiabetic drugs. The presence of islet cell and thyrogastric antibodies can unmask a distinct group of NIDD patients with a high risk of secondary drug failure and subsequent insulin dependency. HLA typing may further help to predict secondary failure in NIDD.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. N. Cook, C. J. Girman, P. P. Stein, C. M. Alexander, and R. R. Holman Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 995 - 1000. [Abstract] [Full Text] [PDF]

				I. Rustenbeck, A. Wienbergen, C. Bleck, and A. Jorns Desensitization of Insulin Secretion by Depolarizing Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S140 - S150. [Abstract] [Full Text] [PDF]

				S. J. Boccuzzi, J. Wogen, J. Fox, J. C.Y. Sung, A. B. Shah, and J. Kim Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population Diabetes Care, August 1, 2001; 24(8): 1411 - 1415. [Abstract] [Full Text] [PDF]

				N. Itabashi, K. Okada, S. Muto, N. Fujita, T. Ohta, J.-i. Miyazaki, Y. Asano, and T. Saito A Novel Enhancer of Insulinotrophic Action by High Glucose (JTT-608) Stimulates Insulin Secretion from Pancreatic beta -Cells via a New Cellular Mechanism J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 953 - 960. [Abstract] [Full Text]

				S. Hashiguchi, T. Yada, and T. Arima A New Hypoglycemic Agent, JTT-608, Evokes Protein Kinase A-Mediated Ca2+ Signaling in Rat Islet {beta}-Cells: Strict Regulation by Glucose, Link to Insulin Release, and Cooperation with Glucagon-Like Peptide-1(7-36)amide and Pituitary Adenylate Cyclase-Activating Polypeptide J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 22 - 30. [Abstract] [Full Text]

				M. Gutierrez, M. Akhavan, L. Jovanovic, and C. M. Peterson Utility of a Short-Term 25% Carbohydrate Diet on Improving Glycemic Control in Type 2 Diabetes Mellitus J. Am. Coll. Nutr., December 1, 1998; 17(6): 595 - 600. [Abstract] [Full Text] [PDF]

				K. L. Jones Non-Insulin Dependent Diabetes in Children and Adolescents: The Therapeutic Challenge Clinical Pediatrics, February 1, 1998; 37(2): 103 - 110. [Abstract] [PDF]